HEИндивидуална стипендия2022–2024

ReCHISVac · Experimental vaccinology, revealing unnatural signatures of protection by repeat controlled human schistosome infection.

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2022-06-01 → 2024-11-30
Финансиране от ЕС: 234 530 €
Участници: 3
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Имунните реакции и антигените при хора, заразени с шистозоми, се анализират чрез биоинформатика и сравнение с данни от Уганда. Това помага за разбирането на защитния механизъм на организма, за да се насочат бъдещи опити за създаване на ваксина срещу това тропическо заболяване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Experimental vaccinology, revealing unnatural signatures of protection by repeat controlled human schistosome infection.

Schistosomiasis is a neglected tropical disease afflicting over 200 million people and causing 300,000 deaths in Africa alone. Whilst infections can be cleared with schistosomocidal drugs, individuals will become rapidly re-infected upon exposure to contaminated water. Partial immunity only develops naturally only after decades of constant infection, and there is no vaccine. Previous schistosome vaccine studies have had limited success, due to a lack of understanding of what constitutes a protective immune response and a lack of pharmaceutical industry support or expertise for development. Here, I proposed to use unique samples from repeat Schistosoma mansoni controlled human infection (Sm-CHI) models to reveal novel antigens and corresponding cellular and cytokine responses that are protective against schistosomiasis. To evaluate how well this protective signature will translate to endemic countries, I performed matched analyses on samples from naturally schistosome infected Ugandan individuals. Antigen-specific antibody and cellular immunology data were combined utilising bioinformatic tools, with the intention of revealing a signatures associated with protection from schistosomiasis. Finally, in a non-academic placement at Batavia Biosciences I performed a systematic review of pre-clinical schistosome vaccines. This review aimed to identify the key parameters of vaccine formulation (such as adjuvant and platform) as well as study design (including challenge dose and timing) that were critical for vaccine efficacy. Together the work aimed to advance immunology of schistosome infection, with the intention of guiding the next generation of schistosome vaccine studies.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Schistosomiasis is a neglected tropical disease afflicting over 200 million people and causing 300,000 deaths in Africa alone. Whilst infections can be cleared with schistosomocidal drugs, individuals will become rapidly re-infected upon exposure to contaminated water. Partial immunity only develops naturally only after decades of constant infection, and there is no vaccine. Previous schistosome vaccine studies have been flawed, due to a lack of understanding of what constitutes a protective immune response, focus on single antigen targets, and a lack of pharmaceutical industry support or expertise for development.Here, I propose to use unique samples from repeat Schistosoma mansoni controlled human infection (Sm-CHI) models to reveal novel antigens and corresponding cellular and cytokine responses that are protective against schistosomiasis. To evaluate how well this protective signature will translate to endemic countries, matched analyses will be performed in samples from naturally schistosome infected Ugandan individuals. Antigen-specific antibody and cellular immunology data will be combined utilising bioinformatic tools to reveal a signature of multiple antigens and immune responses associated with protection from schistosomiasis. Next, in a non-academic placement at Batavia Biosciences, I will develop a pre-clinical development plan to translate the identified protective immune signature into an effective vaccine against human schistosomiasis. This fellowship will form the basis of my future career development, to become an independent researcher in the field of schistosome vaccinology.

Оригинален текст от CORDIS (на английски).

Участници

ACADEMISCH ZIEKENHUIS LEIDEN · LeidenКоординаторНидерландия
BATAVIA BIOSCIENCES BV · LeidenНидерландия
JANSSEN VACCINES & PREVENTION BV · LeidenНидерландия